Skip to content

Agtc stocktwits

Agtc stocktwits

Astrotech Corp. ASTC 2.84 0.06 (2.18%). NASDAQ Updated Jun 8, 2020 10:18 PM Find the latest Applied Genetic Technologies Co (AGTC) stock quote, history, news and other vital information to help you with your stock trading and investing. See Applied Genetic Technologies Co (AGTC) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Adamis Pharmaceuticals Corporation. ADMP 0.66 0.13 (23.76%). NASDAQ Updated Jun 8, 2020 11:59 PM At AGTC we are focused on genetic therapies that can restore visual function in patients with rare inherited conditions. Simple activities such as riding a bike, playing outside, and even the ability to recognize a loved one in a crowd, can be impossible for patients with rare blinding conditions.

ALDX | Complete Aldeyra Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

ALDX | Complete Aldeyra Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Find the latest INTELGENX TECHNOLOGIES CORPORAT (IGXT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. Real-time trade and investing ideas on Applied Genetic Technologies AGTC from the largest community of traders and investors. Current Technical Analysis and interactive chart for $AGTC stock / shares. See the current AGTC Ideas on StockTwits · AGTC Tweets on Twitter. Indicators 

At AGTC we are focused on genetic therapies that can restore visual function in patients with rare inherited conditions. Simple activities such as riding a bike, playing outside, and even the ability to recognize a loved one in a crowd, can be impossible for patients with rare blinding conditions.

Trend Table for AGTC - Applied Genetic Technologies Corporation. AGTC Chart by TradingView StockTwits Facebook Twitter Real Estate Sign Post Installation Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the fiscal quarter ended March 31, 2020 before the market opens on Wednesday, May 13, 2020. To AGTC has the potential to comeback, because the failed data from the phase 1/2 XLRS study used intravitreal injections for patients as opposed to subretinal injections.

Sync with Stocktwits Never miss an important article again, stay on top of your investments and become a better investor today! Get your moat on and sync your watchlist with Stocktwits and get all the latest news for your symbols.

At AGTC we are focused on genetic therapies that can restore visual function in patients with rare inherited conditions. Simple activities such as riding a bike, playing outside, and even the ability to recognize a loved one in a crowd, can be impossible for patients with rare blinding conditions. Capricor Therapeutics Inc. CAPR 4.71 0.43 (9.97%). NASDAQ Updated Jun 8, 2020 8:38 PM Marinus Pharmaceuticals. MRNS 2.85 0.11 (3.83%). NASDAQ Updated Jun 8, 2020 8:52 PM

Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based  

- Administration of AGTC s proprietary adeno-associated virus vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile - GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 20, 2020 -- Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are 6 Wall Street analysts have issued ratings and price targets for Applied Genetic Technologies in the last 12 months. Their average twelve-month price target is $16.50, suggesting that the stock has a possible upside of 216.09%. The high price target for AGTC is $25.00 and the low price target for AGTC is $10.00.

Apex Business WordPress Theme | Designed by Crafthemes